114 related articles for article (PubMed ID: 26780189)
21. HPV-16-related proteins as the serologic markers in cervical neoplasia.
Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
23. Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
Williamson AL; Passmore JA; Rybicki EP
Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392
[TBL] [Abstract][Full Text] [Related]
24. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
25. Laboratory diagnosis of human papillomavirus infection.
Ikenberg H
Curr Probl Dermatol; 2014; 45():166-74. PubMed ID: 24643185
[TBL] [Abstract][Full Text] [Related]
26. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus infection. Recent findings on progression to cervical cancer.
Adimora AA; Quinlivan EB
Postgrad Med; 1995 Sep; 98(3):109-12, 115-6, 120. PubMed ID: 7675735
[TBL] [Abstract][Full Text] [Related]
28. Recent progress in vaccination against human papillomavirus-mediated cervical cancer.
McKee SJ; Bergot AS; Leggatt GR
Rev Med Virol; 2015 Mar; 25 Suppl 1():54-71. PubMed ID: 25752816
[TBL] [Abstract][Full Text] [Related]
29. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
30. [Immunity of the female genital tract mucosa and mechanisms of papillomavirus evasion].
Riethmuller D; Seilles E
J Gynecol Obstet Biol Reprod (Paris); 2000 Dec; 29(8):729-740. PubMed ID: 11139708
[TBL] [Abstract][Full Text] [Related]
31. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus molecular biology and pathogenesis.
Sanclemente G; Gill DK
J Eur Acad Dermatol Venereol; 2002 May; 16(3):231-40. PubMed ID: 12195562
[TBL] [Abstract][Full Text] [Related]
33. Immune evasion mechanisms of human papillomavirus: An update.
Steinbach A; Riemer AB
Int J Cancer; 2018 Jan; 142(2):224-229. PubMed ID: 28865151
[TBL] [Abstract][Full Text] [Related]
34. [Epigenetic alterations in cervical cancer progression].
Ríos-Romero M; Soto-Valladares AG; Piña-Sánchez P
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S212-7. PubMed ID: 26462519
[TBL] [Abstract][Full Text] [Related]
35. IMMUNONUTRITION IN CERVICAL CANCER: IMMUNE RESPONSE MODULATION BY DIET.
Medina-Contreras O; Luvián-Morales J; Valdez-Palomares F; Flores-Cisneros L; Sánchez-López MS; Soto-Lugo JH; Castro-Eguiluz D
Rev Invest Clin; 2020; 72(4):219-230. PubMed ID: 33064687
[TBL] [Abstract][Full Text] [Related]
36. Current Advances in the Application of Raman Spectroscopy for Molecular Diagnosis of Cervical Cancer.
Ramos IR; Malkin A; Lyng FM
Biomed Res Int; 2015; 2015():561242. PubMed ID: 26180802
[TBL] [Abstract][Full Text] [Related]
37. A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.
Kovachev SM
Infect Drug Resist; 2021; 14():2039-2049. PubMed ID: 34103950
[TBL] [Abstract][Full Text] [Related]
38. Immune deviation and cervical carcinogenesis.
Smola S
Papillomavirus Res; 2019 Jun; 7():164-167. PubMed ID: 30980967
[TBL] [Abstract][Full Text] [Related]
39. Immunosignature: Serum Antibody Profiling for Cancer Diagnostics.
Chapoval AI; Legutki JB; Stafford P; Trebukhov AV; Johnston SA; Shoikhet YN; Lazarev AF
Asian Pac J Cancer Prev; 2015; 16(12):4833-7. PubMed ID: 26163599
[TBL] [Abstract][Full Text] [Related]
40. MiRNA in cervical cancer: Diagnosis to therapy: Systematic review.
Endale HT; Mariye YF; Negash HK; Hassen FS; Asrat WB; Mengstie TA; Tesfaye W
Heliyon; 2024 Feb; 10(3):e24398. PubMed ID: 38317930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
